[10]
*Data from 1000 Genomes Phase 3: EUR population (n=503 1.07 [24] Coronary artery disease ABO rs579459 T 1.1×10
-07
1.25 [25] Heart failure ABO rs579459 T 1.2×10
-06 0.90 [23] Heart attack/myocardial infarction ABO rs579459 T 0.0001 0.94 [23] Ischemic heart diseases ABO rs579459 T 0.0006 0.97 [23] Atherosclerosis ABO rs579459 T 0.001 0.86 [23] Heart/cardiac problem ABO rs579459 T 0.01 0.97 [23] Heart attack/myocardial infarction VCAM1 rs6660837 A 0.04 1.03 [23] Heart/cardiac problem PNPLA3 rs738409 C 0.003 1.03 [23] Ischemic heart diseases PNPLA3 rs738409 C 0.02 1.02 [23] Heart failure ABO rs8176719 T 1.3×10
-05 0.92 [23] Heart attack/myocardial infarction ABO rs8176719 T 0.0001 0.95 [23] Atherosclerosis ABO rs8176719 T 0.002 0.88 [23] Ischemic heart diseases ABO rs8176719 T 0.006 0.98 [23] Heart/cardiac problem ABO rs8176719 T 0.01 0.98 [23] Coronary artery disease VCAM1 rs3176863 A 0.03 1.10 [25] Postoperative myocardial infarction ICAM1 rs5498 G 0.009 1.88 [26] Fig A. Relationship between ABO blood groups and soluble E-selectin level in the current study as well as
Blann et al. [27] and Qi et al. [7] n= 
